Cite
Sorafenib as a Bridging Therapy to Liver Transplantation in Patients with Hepatocellular Carcinoma: A First Experience from a Pilot Prospective Study
MLA
Vitale, A., et al. Sorafenib as a Bridging Therapy to Liver Transplantation in Patients with Hepatocellular Carcinoma: A First Experience from a Pilot Prospective Study. Jan. 2011. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3657..e7cd40331f9c0a2b482436a524ab25f1&authtype=sso&custid=ns315887.
APA
Vitale, A., Salinas, F., Ramirez Morales, R., D’Amico, F., Gringeri, E., Boccagni, P., Neri, D., Zanus, G., Burra, P., & Cillo, U. (2011). Sorafenib as a Bridging Therapy to Liver Transplantation in Patients with Hepatocellular Carcinoma: A First Experience from a Pilot Prospective Study.
Chicago
Vitale, A, F Salinas, R Ramirez Morales, F D’Amico, Enrico Gringeri, P Boccagni, D Neri, G Zanus, Patrizia Burra, and Umberto Cillo. 2011. “Sorafenib as a Bridging Therapy to Liver Transplantation in Patients with Hepatocellular Carcinoma: A First Experience from a Pilot Prospective Study,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3657..e7cd40331f9c0a2b482436a524ab25f1&authtype=sso&custid=ns315887.